FDA Approves Unknown Drug — TEVA PHARMS USA

TEVA PHARMS USA reported the approval of its Abbreviated New Drug Application (ANDA 205807) on March 10, 2017, a milestone that positions the company to enter the generic market following the patent expiration of the reference product. The filing is expected to generate additional opportunity for U.S. sales as it challenges a branded pipeline.